Researchers conducted a retrospective, observational study of 177 patients with CRSwNP from January 1, 2016, to December 29, 2021.
Investigators assessed the annualized asthma exacerbation rate (AAER) and the annualized rate of asthma exacerbations requiring hospitalization over 52 weeks.
Researchers conducted on a pooled safety analysis of lebrikizumab during the 52-week placebo-controlled period.
About 67% of children in the active peanut patch cohort and 33.5% in the placebo patch cohort achieved the primary efficacy endpoint.
White women were less likely to receive a liver transplant compared with White men, after adjustment for comorbidities and socioeconomic and demographic factors.
The retrospective analysis included adult patients with IBD who had outpatient colonoscopies from January 2011 to October 2021 at 3 large academic medical centers.
Participants had a 5-day placebo run-in period and then were randomly assigned to pancrelipase (72,000 LU/meal; 36,000 LU/snack) or placebo for a 7-day, double-blind period.
After COVID-19, the risk for GI diagnoses and AN was increased, compared with the other control populations, except for patients with GI diagnoses after CMV.
The data were compared with the 2018 ACG and 2020 AGA guidelines for UC and the 2019 ACG and 2021 AGA guidelines for CD.
Kaplan-Meier analyses were used to estimate the mean time to treatment switch, and all-cause health care resource use and costs (2020 $US) were compiled and compared for the 2 cohorts.
